Recombinant Chicken ARHGDIB

• Cat.No.: ARHGDIB-4780C
• Product Overview: Recombinant Chicken ARHGDIB full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Chicken
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: ARHGDIB Rho GDP dissociation inhibitor (GDI) beta [ Gallus gallus (chicken) ]
• Official Symbol: ARHGDIB
• Gene ID: 417941
• Protein Refseq: NP_001264293

Reviews

12/23/2022

a manufacturer that offers reliable and high-quality ARHGDIB protein can significantly enhance the research experience.

06/18/2021

With their commitment to delivering high-quality products, I am confident in achieving successful outcomes and advancing my research.

11/10/2020

By using ARHGDIB protein, I can gain insights into the underlying molecular processes contributing to amyloidosis, which can ultimately aid in the development of novel therapeutic strategies.

09/16/2019

Such a manufacturer can provide technical expertise and guidance throughout the experimental process, from experimental design to troubleshooting and data analysis.

11/04/2018

In addition to the advantages of ARHGDIB protein, collaborating with a manufacturer that offers exceptional support can greatly benefit researchers.

09/30/2017

The manufacturer plays a crucial role in supporting my research with their extensive expertise and resources.

05/06/2017

This assurance enables me to confidently utilize the ARHGDIB protein in my research, knowing that it will consistently deliver reliable and accurate results.

03/14/2016

the manufacturer facilitates access to the latest scientific advancements and developments related to ARHGDIB protein research.

Q&As

Does ARHGDIB have any isoforms or splice variants?

ARHGDIB does not have known isoforms or splice variants. It is a single gene that encodes a conserved protein across different species and tissues.

How does ARHGDIB regulate Rho GTPases?

ARHGDIB binds to GTP-bound Rho GTPases and inhibits their activity by preventing their dissociation from the cell membrane, thus keeping them inactive.

Can mutations in the ARHGDIB gene lead to any genetic disorders?

Mutations in the ARHGDIB gene have not been clearly associated with any genetic disorders. However, further research is needed to explore any potential disease-causing mutations in ARHGDIB.

Does ARHGDIB have any other biological functions?

Yes, ARHGDIB has been reported to play a role in other cellular processes, including vesicular trafficking, cell adhesion, and apoptosis.

Can changes in ARHGDIB expression be used as a diagnostic marker?

The potential diagnostic utility of ARHGDIB expression changes is currently not well established. However, alterations in ARHGDIB expression levels have been observed in certain cancers, suggesting its potential as a diagnostic marker in those specific contexts.

What are the similarities and differences between ARHGDIA and ARHGDIB?

Both ARHGDIA and ARHGDIB are members of the Rho GTPase regulator family and play roles in modulating Rho GTPase activity. However, they have distinct amino acid sequences and may have different tissue expression patterns and specific functions in cellular processes.

Can ARHGDIB interact with other proteins involved in cell signaling pathways?

Yes, ARHGDIB can interact with various proteins involved in cell signaling pathways, particularly those associated with Rho GTPase signaling. These include guanine nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs), and effector proteins that mediate downstream signaling events.

How does ARHGDIB affect cell motility?

ARHGDIB inhibits Rho GTPases, which are central regulators of cell motility. By keeping Rho GTPases inactive, ARHGDIB can suppress cell migration and invasion.

Does ARHGDIB have any known post-translational modifications?

Yes, ARHGDIB can undergo post-translational modifications such as phosphorylation, acetylation, and ubiquitination, which can regulate its stability, function, and cellular localization.

Are there any known diseases or conditions associated with dysregulation of ARHGDIB?

Although not extensively studied, some studies have suggested a potential link between ARHGDIB dysregulation and certain diseases, including cancer, neuronal disorders, and cardiovascular diseases. However, more research is needed to establish these associations conclusively.

Are there any known diseases associated with ARHGDIB?

Although ARHGDIB has not been extensively studied in the context of diseases, alterations in its expression or function have been implicated in certain cancers, such as hepatocellular carcinoma and colorectal cancer.

Are there any knockout studies done on ARHGDIB?

Yes, knockout studies have been performed on ARHGDIB in animal models to investigate its physiological functions. These studies have provided insights into the role of ARHGDIB in various cellular processes and its impact on overall organismal development.

Does ARHGDIB play a role in any other cellular processes besides cell motility?

Yes, ARHGDIB has been implicated in various cellular processes, including cell adhesion, cytoskeleton organization, cell polarity, cell division, and vesicle trafficking.

Could modulation of ARHGDIB expression or activity have therapeutic implications in cancer treatment?

Modulation of ARHGDIB expression or activity may have therapeutic implications in cancer treatment. Since Rho GTPase signaling is involved in cancer progression and metastasis, targeting ARHGDIB might help inhibit these processes and improve treatment outcomes.

Can ARHGDIB be used as a therapeutic target?

The potential of ARHGDIB as a therapeutic target is still being explored. Modulation of ARHGDIB expression or activity could have therapeutic implications in certain diseases, particularly those involving aberrant Rho GTPase signaling. However, further studies are needed to assess the feasibility and efficacy of targeting ARHGDIB for therapeutic interventions.

Is there any ongoing research focused on ARHGDIB?

Yes, ongoing research is focused on further understanding the role of ARHGDIB in cellular processes, its potential involvement in diseases, and its therapeutic implications. Researchers are also exploring the underlying molecular mechanisms of ARHGDIB regulation and its interactions with other proteins.

Is there any research on the therapeutic potential of targeting ARHGDIB?

As of now, there is limited research on targeting ARHGDIB for therapeutic purposes. However, further investigations are needed to explore its potential as a therapeutic target in various diseases.

Are there any known binding partners of ARHGDIB?

ARHGDIB has been reported to interact with several proteins, including Rho GTPases, specific guanine nucleotide exchange factors (GEFs), and other regulatory proteins involved in Rho GTPase signaling.